S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.43 (-6.06%)
AMD   176.54 (-0.82%)
BABA   74.59 (-3.98%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.61 (+1.05%)
DIS   110.80 (+1.26%)
AMC   4.99 (+3.74%)
PFE   27.04 (+0.56%)
PYPL   60.25 (+0.15%)
XOM   104.32 (+0.28%)

Ligand Pharmaceuticals (LGND) SEC Filings & 10K Form

$84.35
-4.85 (-5.44%)
(As of 04:00 PM ET)

Recent Ligand Pharmaceuticals SEC Filings

DateFilerForm TypeView
02/27/2024
6:24 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/16/2024
7:10 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/16/2024
7:10 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2024
5:26 AM
Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
Form SC 13G
02/13/2024
2:39 PM
JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
02/12/2024
6:42 PM
GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G
01/22/2024
1:03 PM
BlackRock Inc. (Filed by)
Ligand Pharmaceuticals (Subject)
Form SC 13G/A
01/04/2024
3:07 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/04/2024
3:07 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/06/2023
2:27 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/01/2023
7:25 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/18/2023
8:03 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2023
3:36 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/27/2023
7:38 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/26/2023
3:41 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/25/2023
5:12 PM
Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/25/2023
3:44 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/18/2023
4:26 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2023
3:20 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/10/2023
5:42 PM
Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/21/2023
8:28 AM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:52 PM
Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:53 PM
Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:54 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:55 PM
LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2023
5:55 PM
Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/18/2023
4:18 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2023
2:43 PM
Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2023
6:07 PM
Ligand Pharmaceuticals (Subject)
Sabba Stephen L (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/10/2023
6:15 PM
KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2023
3:06 PM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/28/2023
4:00 PM
Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2023
7:02 AM
Ligand Pharmaceuticals (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:LGND) was last updated on 2/28/2024 by MarketBeat.com Staff